SCHEMBL4179470

SCHEMBL4179470

N#Cc1ccc(Oc2ccccc2C(F)(F)F)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.63
SLC22A12 Q96S37 4/20 0.49
STK39 Q9UEW8 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KCNH2 Q12809 1/20 0.44
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
ERBB3 P21860 1/20 0.43
ERBB4 Q15303 1/20 0.43
TRPV4 Q9HBA0 1/20 0.41
SCN9A Q15858 2/20 0.39
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
NR3C2 P08235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23409847 0.88 MRGPRX4 (0.47) ARSLC22A12MRGPRX4TRPV4SCN9A
SCHEMBL29788295 0.88 MRGPRX4 (0.47) ARSLC22A12MRGPRX4TRPV4SCN9A
SCHEMBL5368943 0.86 AR (0.61) ARSLC22A12TRPV4
SCHEMBL5498698 0.85 AR (0.53) ARSLC22A12STK39MRGPRX4SLC6A4
SCHEMBL4183156 0.81 AR (0.68) ARSLC22A12MRGPRX4SLC6A4SLC6A3
SCHEMBL4168825 0.78 AR (1.00) ARMRGPRX4SLC6A4SLC6A3KCNH2
SCHEMBL4183157 0.78 AR (0.73) ARSLC22A12MRGPRX4SLC6A4SLC6A3
SCHEMBL2381155 0.78 ESRRA (0.48) ARSLC22A12MRGPRX4SLC6A4SLC6A3
SCHEMBL922922 0.77 AR (0.50) ARSLC22A12
SCHEMBL4181361 0.75 AR (0.65) ARSLC22A12STK39MRGPRX4SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105349-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2009-04-23 US claimed
EP-1781280-A2 ANDROGEN MODULATORS Warner-Lambert Company LLC (US) 2007-05-09 EP claimed
WO-2006018723-A2 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2006-02-23 WO claimed
US-20090105349-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2009-04-23 US disclosed
US-20090105349-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2009-04-23 US disclosed
US-20090105349-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105349-A1 ANDROGEN MODULATORS AR, NR5A1, SHBG AR 1/4885SLC22A12 3958/4885STK39 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.